Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide

We designed this study to identify the prognostic value of baseline prognostic nutritional index (PNI) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. 101 mCRPC patients were included. PNI was calculated using formula 10 x serum a...

Full description

Saved in:
Bibliographic Details
Published in:Actas urológicas españolas (English ed.) 2022-06, Vol.46 (5), p.301-309
Main Authors: Küçükarda, A., Gökyer, A., Gökmen, İ., Özcan, E., Hacıoğlu, M.B., Erdoğan, B., Uzunoğlu, S., Çiçin, İ.
Format: Article
Language:eng ; spa
Subjects:
Abiraterone acetate
Acetato de abiraterona
Castration-resistant prostate cancer
Cáncer de próstata resistente a la castración
Enzalutamida
Enzalutamide
Prognostic nutritional index
Índice nutricional pronóstico
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We designed this study to identify the prognostic value of baseline prognostic nutritional index (PNI) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. 101 mCRPC patients were included. PNI was calculated using formula 10 x serum albumin value (gr/dL) + 0.005 × total lymphocyte count (per mm3). ROC analysis was used for determining prognostic PNI value. The statistically significant cut-off value for PNI was 46.62. Initial PSA response and PSA kinetics (early PSA response and 30 %–50%–90% PSA response at any time) were much better in PNI > 46.62 group than the PNI ≤ 46.62 group (p 46.62 was an independent predictor of PSA-PFS (HR: 0.42, p 
ISSN:2173-5786
2173-5786
DOI:10.1016/j.acuroe.2021.12.005